Navigation

Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

Bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma

Status: In development
Expected date of issue: TBC
Referral date: May 2012
Process: STA
Notes:

Scoped as part of Batch 22

Topic area:
  • Cancer
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Project manager: Bijal Joshi
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
4 February 2013 The manufacturer is unable to provide an evidence submission for this appraisal by 22 February 2013. The appraisal is suspended whilst we consider the next steps. 
Top


 

Key documents

This page was last updated: 04 February 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.